Personalized ctDNA Micro-Panels for Monitoring and Predicting Clinical Outcomes in Triple-Negative Breast Cancer

Explore a concise conference talk on personalized circulating tumor DNA (ctDNA) micro-panels for monitoring and predicting clinical outcomes in triple-negative breast cancer patients. Delve into Erica K. Barnell's presentation from the 2022 Cancer Genomics Consortium Annual Meeting, which discusses the potential of ctDNA technology in improving cancer diagnosis and treatment. Gain insights into how these micro-panels can be utilized to accurately detect genomic alterations and guide appropriate therapy decisions. Learn about the Cancer Genomics Consortium's mission to promote best practices in clinical cancer genomics and their efforts to become the authoritative organization for guidance in this field.

Personalized ctDNA Micro-Panels Monitor & Predict Clinical Outcomes for Patients Triple-Negative